Last reviewed · How we verify
AT-527 single dose
AT-527 is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, thereby blocking viral replication.
AT-527 is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, thereby blocking viral replication. Used for Treatment of SARS-CoV-2 infection.
At a glance
| Generic name | AT-527 single dose |
|---|---|
| Also known as | Bemnifosbuvir |
| Sponsor | Atea Pharmaceuticals, Inc. |
| Drug class | nucleoside analog |
| Target | viral RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Mechanism of action
AT-527 specifically targets the RNA-dependent RNA polymerase of viruses, which is essential for the transcription and replication of viral RNA. By inhibiting this enzyme, AT-527 prevents the virus from producing new viral particles, thus reducing viral load and potentially alleviating disease symptoms.
Approved indications
- Treatment of SARS-CoV-2 infection
Common side effects
- headache
- nausea
Key clinical trials
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone (PHASE1)
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) (PHASE1)
- Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function (PHASE1)
- Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir (PHASE1)
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin (PHASE1)
- Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function (PHASE1)
- Study of AT-527 in Subjects With Normal and Impaired Renal Function (PHASE1)
- Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AT-527 single dose CI brief — competitive landscape report
- AT-527 single dose updates RSS · CI watch RSS
- Atea Pharmaceuticals, Inc. portfolio CI